lung cancer patients undergoing thoracic surgery MedDRA version: 9.1 Level: LLT Classification code 10026532 Term: Malignant neoplasm of thorax
Conditions
Interventions
Product Name: Metoprolol
Pharmaceutical Form: Tablet
INN or Proposed INN: Metoprolol
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Product Name: losartan
Ph
Sponsors
ISTITUTO EUROPEO DI ONCOLOGIA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male or female patients older than 18 years. Thoracic surgery for lung cancer High peri-operative values of NT-proBNP. Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Intollerance to metoprolol and/or losartan History of heart failure Ejection fraction <50% Permanent FA Treatment with antiarythmics, beta blockers, angiotensin II blockers, ACE inhibitors Sistolic blood pressure < 95 mmHg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: evaluate the possibility to prevent FA after thoracic surgery through beta-blocker administration vs an angiotensin II inhibitor (losartan)in high risk patients with high peri-operative values of NT-proBNP;Secondary Objective: to evaluate if prevention correlates with a reduction of NT-proBNP levels.;Primary end point(s): incidence of FA episodes after surgery | — |
Countries
Italy
Outcome results
None listed